COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report

M. Breccia, E. Abruzzese, V. Accurso, I. Attolico, S. Barulli, M. Bergamaschi, G. Binotto, M. Bocchia, M. Bonifacio, G. Caocci, I. Capodanno, F. Castagnetti, F. Cavazzini, E. Crisà, M. Crugnola, M. Stella De Candia, C. Elena, C. Fava, S. Galimberti, A. GozziniG. Gugliotta, T. Intermesoli, A. Iurlo, G. La Barba, R. Latagliata, S. Leonetti Crescenzi, L. Levato, G. Loglisci, A. Lucchesi, L. Luciano, F. Lunghi, D. Luzi, A. Malato, M. Cristina Miggiano, M. Pizzuti, P. Pregno, D. Rapezzi, G. Rege-Cambrin, G. Rosti, S. Russo, R. Sancetta, A. Rita Scortechini, F. Sorà, P. Sportoletti, F. Stagno, A. Tafuri, M. Tiribelli, R. Foà, G. Saglio

Research output: Contribution to journalArticlepeer-review

Abstract

Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalBritish Journal of Haematology
Volume196
Issue number3
DOIs
Publication statusPublished - 2022

Keywords

  • Aged
  • COVID-19
  • Disease-Free Survival
  • Female
  • Humans
  • Italy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Male
  • Middle Aged
  • Pandemics
  • Retrospective Studies
  • SARS-CoV-2
  • Survival Rate
  • asciminib
  • bosutinib
  • dasatinib
  • imatinib
  • nilotinib
  • ponatinib
  • protein tyrosine kinase inhibitor
  • adult
  • aged
  • Article
  • assisted ventilation
  • cancer patient
  • chronic myeloid leukemia
  • cohort analysis
  • comorbidity
  • controlled study
  • coronavirus disease 2019
  • disease severity
  • drug response
  • female
  • hospitalization
  • human
  • incidence
  • intensive care unit
  • leukemia remission
  • major clinical study
  • male
  • mortality rate
  • pandemic
  • prevalence
  • quarantine
  • retrospective study
  • diagnosis
  • disease free survival
  • epidemiology
  • middle aged
  • mortality
  • survival rate

Fingerprint

Dive into the research topics of 'COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report'. Together they form a unique fingerprint.

Cite this